Compare Edwards Lifesciences Corporation Common Stock (EW) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $87.17 (market cap $49.83B), while GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B). The key difference: Edwards Lifesciences Corporation Common Stock is the larger of the two by market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EW | GEHC | |
|---|---|---|
Market Cap | $49.83B | $30.93B |
Volume | 4,036,375 | 5,033,451 |
Sector | Health | Health |
52-Week High | $95.18 | $88.16 |
52-Week Low | $72.65 | $59.48 |
Enterprise Value | $46.28B | $39.39B |
Dividend Yield | — | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Edwards Lifesciences (EW) trades at $85.27, down 1.3% with bearish technical signals. The company maintains strong fundamentals with 77.84% gross margins and recent FDA approval for the AUTUS pediatric valve. Despite a high P/E of 50.76, analysts project 20% upside to the $102.44 consensus target. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss.
EW faces valuation concerns with declining net income margins from 17.69% to 15.43% year-over-year. Technical resistance at $86-89 and negative cash flow trends present near-term challenges. However, institutional accumulation and zero sell ratings suggest long-term confidence in structural heart growth platforms.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
